Fundsmith Investment Services LTD. Grows Position in Zoetis Inc. $ZTS

Fundsmith Investment Services LTD. raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 34.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,175,723 shares of the company’s stock after purchasing an additional 303,950 shares during the quarter. Zoetis comprises 2.7% of Fundsmith Investment Services LTD.’s holdings, making the stock its 16th biggest position. Fundsmith Investment Services LTD. owned approximately 0.27% of Zoetis worth $172,032,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC raised its stake in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC lifted its position in Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares during the period. Sivia Capital Partners LLC grew its stake in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Zoetis during the 2nd quarter valued at about $814,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $115.62 on Friday. The firm has a market capitalization of $48.81 billion, a P/E ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95. The stock has a 50-day simple moving average of $125.34 and a two-hundred day simple moving average of $131.91. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a fifty-two week low of $114.47 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research analyst reports. Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Stifel Nicolaus decreased their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Six equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.